Hansoh Pharmaceutical Group Company Limited
HKEX:3692.HK
17.7 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 10,103.806 | 9,382.41 | 9,935.141 | 8,690.234 | 8,682.746 | 7,722.278 | 6,185.537 | 5,432.96 |
| Cost of Revenue
| 1,030.863 | 870.19 | 870.389 | 803.411 | 737.529 | 603.1 | 455.171 | 397.279 |
| Gross Profit
| 9,072.943 | 8,512.22 | 9,064.752 | 7,886.823 | 7,945.217 | 7,119.178 | 5,730.366 | 5,035.681 |
| Gross Profit Ratio
| 0.898 | 0.907 | 0.912 | 0.908 | 0.915 | 0.922 | 0.926 | 0.927 |
| Reseach & Development Expenses
| 2,097.046 | 1,693.314 | 1,797.012 | 1,252.246 | 1,120.681 | 881.288 | 575.544 | 403.065 |
| General & Administrative Expenses
| 709.844 | 597.46 | 943.423 | 758.641 | 777.692 | 356.277 | 260.48 | 235.611 |
| Selling & Marketing Expenses
| 3,531.163 | 3,550.23 | 3,427.818 | 3,103.018 | 3,266.38 | 3,208.68 | 2,704.2 | 2,378.04 |
| SG&A
| 4,241.007 | 4,147.69 | 4,371.241 | 3,861.659 | 4,044.072 | 3,564.957 | 2,964.68 | 2,613.651 |
| Other Expenses
| -165.405 | -168.235 | 99.246 | 4.043 | 13.5 | 24.787 | 28.066 | 14.053 |
| Operating Expenses
| 6,233.622 | 5,837.166 | 5,965.703 | 4,950.795 | 5,123.622 | 4,846.637 | 3,839.512 | 3,254.352 |
| Operating Income
| 2,679.347 | 2,607.483 | 2,820.591 | 2,772.918 | 2,780.464 | 2,320.237 | 1,928.645 | 1,807.677 |
| Operating Income Ratio
| 0.265 | 0.278 | 0.284 | 0.319 | 0.32 | 0.3 | 0.312 | 0.333 |
| Total Other Income Expenses Net
| 1,086.808 | 340.945 | 479.491 | 325.381 | 220.461 | -10.912 | 4.146 | -3.399 |
| Income Before Tax
| 3,766.155 | 2,948.428 | 3,300.082 | 3,098.299 | 3,000.925 | 2,309.325 | 1,932.791 | 1,804.278 |
| Income Before Tax Ratio
| 0.373 | 0.314 | 0.332 | 0.357 | 0.346 | 0.299 | 0.312 | 0.332 |
| Income Tax Expense
| 488.652 | 364.681 | 587.18 | 529.392 | 444.183 | 406.277 | 337.318 | 328.244 |
| Net Income
| 3,277.503 | 2,583.747 | 2,712.902 | 2,568.907 | 2,556.742 | 1,903.048 | 1,595.473 | 1,476.034 |
| Net Income Ratio
| 0.324 | 0.275 | 0.273 | 0.296 | 0.294 | 0.246 | 0.258 | 0.272 |
| EPS
| 0.55 | 0.44 | 0.46 | 0.44 | 0.47 | 0.33 | 0.28 | 0.26 |
| EPS Diluted
| 0.52 | 0.44 | 0.44 | 0.44 | 0.47 | 0.33 | 0.28 | 0.26 |
| EBITDA
| 4,062.916 | 2,931.855 | 3,084.012 | 2,989.268 | 2,964.139 | 2,479.333 | 2,066.658 | 1,928.979 |
| EBITDA Ratio
| 0.402 | 0.312 | 0.31 | 0.344 | 0.341 | 0.321 | 0.334 | 0.355 |